The U.S. Food and Drug Administration has approved a new breast cancer chemotherapy drug called Ixempra for the treatment of advanced breast cancer in women who haven't responded to three other types of chemotherapy.

Bristol-Myers Squibb Co., which makes Ixempra, said was the drug is approved for use with the chemotherapy drug capecitabine (brand name Xeloda) for treatment of women with breast cancer that's spread to other parts of the body

The Food and Drug Administration (FDA) on Tuesday reportedly approved two drugs for the treatment of advanced breast cancer in women who have stopped responding to other drug forms.

The GlaxoSmithKline PLC drug, Tykerb (lapatinib) in combination with Xeloda (capecitabine) is to be taken once daily in pill form by women who have received prior treatment with the intravenous drug Herceptin and older chemotherapy drugs called taxanes and anthracyclines